U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H28N4O2.C4H4O4
Molecular Weight 544.5983
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ZALDARIDE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CC4(CN1CCC(CC1)N2C(=O)NC3=CC=CC=C23)OCC5=C(C=CC=C5)N6C=CC=C46

InChI

InChIKey=NGODOSILXOFQPH-BTJKTKAUSA-N
InChI=1S/C26H28N4O2.C4H4O4/c1-26(24-11-6-14-29(24)22-9-4-2-7-19(22)17-32-26)18-28-15-12-20(13-16-28)30-23-10-5-3-8-21(23)27-25(30)31;5-3(6)1-2-4(7)8/h2-11,14,20H,12-13,15-18H2,1H3,(H,27,31);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE
Molecular Formula C26H28N4O2
Molecular Weight 428.5261
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Zaldaride is a calmodulin antagonist known to produce inhibition of calmodulin-dependent voltage-gated ion channels including those of Ca2+, Na+, and K+. Zaldaride was also observed to inhibit nicotinic acetylcholine receptor (nAChR) channel currents. Zaldaride has been studied in clinical trials as a potential treatment for travelers diarrhea.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C
3
Target ID: Q14123
Gene ID: 5137.0
Gene Symbol: PDE1C
Target Organism: Homo sapiens (Human)
Inhibitor
8297
 3.3 µM [IC50]
Inhibitor
8297
 0.81 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Phase III
656
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity.
1987 May
The calmodulin inhibitor CGS 9343B inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells.
2015 Jun 15
Patents

Patents

20150265627
2

Sample Use Guides

In Vivo Use Guide
Treatment of traveler's diarrhea: 20 mg zaldaride maleate four times per day
Route of Administration: Oral
In Vitro Use Guide
Zaldaride (CGS 9343B) inhibited Kv currents in rabbit coronary arterial smooth muscle cells in a concentration-dependent manner, with a half-maximal inhibitory concentration (IC50) value of 0.81uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:45:36 UTC 2023
Edited
by admin
on Fri Dec 15 15:45:36 UTC 2023
Record UNII
K7SG01P7NJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZALDARIDE MALEATE
MART.   MI  
Common Name English
ZALDARIDE MALEATE [MI]
Common Name English
ZALDARIDE MALEATE [MART.]
Common Name English
1,3-DIHYDRO-1-(1-((4-METHYL-4H,6H-PYRROLO(1,2-A)(4,1)BENZOXAZEPIN-4-YL)METHYL)-4-PIPERIDINYL)-2H-BENZIMIDAZOL-2-ONE MALEATE
Systematic Name English
CGS-9434B
Code English
(±)-1-(1-((4-METHYL-4H,6H-PYRROLO(1,2-A)(4,1)BENZOXAZEPIN-4-YL)METHYL)-4-PIPERIDYL)-2-BENZIMIDAZOLINONE MALEATE
Systematic Name English
ZY-17617B
Code English
KW-5617
Code English
Code System Code Type Description
FDA UNII
K7SG01P7NJ
Created by admin on Fri Dec 15 15:45:36 UTC 2023 , Edited by admin on Fri Dec 15 15:45:36 UTC 2023
PRIMARY
CAS
109826-27-9
Created by admin on Fri Dec 15 15:45:36 UTC 2023 , Edited by admin on Fri Dec 15 15:45:36 UTC 2023
PRIMARY
PUBCHEM
6450522
Created by admin on Fri Dec 15 15:45:36 UTC 2023 , Edited by admin on Fri Dec 15 15:45:36 UTC 2023
PRIMARY
MERCK INDEX
m11578
Created by admin on Fri Dec 15 15:45:36 UTC 2023 , Edited by admin on Fri Dec 15 15:45:36 UTC 2023
PRIMARY Merck Index
Related Record Type Details
Structure of ZALDARIDE
PARENT -> SALT/SOLVATE
Structure of MALEIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZALDARIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966